Previous 10 | Next 10 |
2023-11-10 16:05:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-11-09 13:17:55 ET More on Eli Lilly Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype? Eli Lilly and Co (LLY) Q3 2023 Earnings Conference Call Transcript Eli Lilly and Company 2023 Q3 - Results - Earnings Call Presentation Eli L...
NORTHAMPTON, MA / ACCESSWIRE / November 9, 2023 / Gilead Sciences / Dr. Shringar Rao's inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs. Even as an early-career researcher, she has a distinct and ambitious m...
2023-11-09 08:45:53 ET Palm Beach, FL – November 9, 2023 – FinancialNewsMedia.com News Commentary – According to the American Cancer Society projections, there were around 9,440 new instances (3,150 in men and 6,290 in women) and about 1,670 fatalities (930 ...
2023-11-08 12:11:21 ET More on Gilead Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Gilead Sciences Stock Is Cheap, With Broad Pipeline Gilead Sciences Non-GAAP EPS of $2.29 ...
2023-11-07 21:15:17 ET Image source: The Motley Fool. Gilead Sciences (NASDAQ: GILD) Q3 2023 Earnings Call Nov 07, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
2023-11-07 20:42:03 ET Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Conference Call November 07, 2023, 04:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief ...
2023-11-07 16:27:20 ET More on Gilead Sciences Full Gilead Sciences earnings info Gilead Sciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Gilead Sciences Stock Is Cheap, With Broad Pipeline Gilead Sciences: Does The Stocks...
2023-11-07 16:05:48 ET More on Gilead Sciences Gilead Sciences Stock Is Cheap, With Broad Pipeline Gilead Sciences: Does The Stocks Reward Outweigh The Risk Gilead Sciences: A Healthy Buy With Solid Dividend Gilead’s HIV business in focus with Q3 resul...
Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales Increased 33% Year-Over-Year to $769 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operati...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...